Business Context and Reporting Period
This Form 8-K, filed on August 7, 2015, reports that Intrexon Corporation (the registrant) entered into a definitive agreement to acquire Oxitec Limited, a pioneer in biological insect control solutions. The transaction involves the acquisition of all issued and to-be-issued share capital of Oxitec, a company focused on controlling disease-spreading mosquitoes and crop pests using sterile, self-limiting insects.
Key Financial Metrics and Transaction Structure
The total consideration for the acquisition is approximately $160 million, structured as follows:
- Cash Consideration: $80 million payable upon closing.
- Stock Consideration: 1,372,212 shares of Intrexon common stock, valued at approximately $80 million based on the 20-day volume-weighted average price prior to signing.
The stock consideration is split into two tranches:
- Immediate Issuance: 857,633 shares (approx. $50 million) on the Closing Date.
- Deferred Issuance: 514,579 shares (approx. $30 million) 18 months post-closing, subject to reduction for indemnification claims.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for Intrexon or Oxitec, as this is a current report regarding a material agreement rather than a periodic financial statement.
Material Changes and Transaction Terms
The primary material change is the entry into the Purchase Agreement to acquire Oxitec. Key terms include:
- Participation: Sellers hold approximately 80% of Oxitec's capital. Holders of warrants, convertible loans, and options are invited to participate on the same terms. Non-participating shareholders will be required to sell their securities under Oxitec's Articles of Association.
- Adjustments: Consideration is subject to net cash and working capital adjustments. The stock portion may decrease by $750,000 (with a corresponding cash increase) if certain equity holders cannot make necessary representations for a registration exemption.
- Restrictions: Sellers are restricted from disposing of the Stock Consideration for 90 days post-closing. Intrexon must register the stock for resale within 90 business days of closing.
Guidance, Outlook, and Risks
Outlook: Consummation of the transaction is anticipated in the second half of 2015, subject to customary closing conditions, including the delivery of audited financial statements and resolution of option-related matters.
Risks and Contingencies: The filing highlights several risks that could prevent the transaction or alter outcomes:
- Failure to satisfy conditions precedent.
- Regulatory actions preventing consummation.
- Material adverse effects on either party's business.
- Volatility in Intrexon's share price affecting the value of the stock consideration.
- Disruption of management attention during the pending transaction.
Intrexon explicitly states it does not undertake an obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and whether the transaction was consummated in the second half of 2015.
- Confirm the final number of shares issued and the final cash amount paid after working capital adjustments.
- Review the full text of the Purchase Agreement (Exhibit 2.1) for specific indemnification clauses and termination rights.
- Monitor regulatory approvals required for Oxitec's technology and the cross-border nature of the acquisition.
- Check subsequent filings for the registration statement regarding the resale of the Stock Consideration.